Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Thomas_McCourt
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
46333X108
|
| gptkbp:filingsInclude |
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001446847
|
| gptkbp:focusArea |
gastrointestinal diseases
|
| gptkbp:foundedYear |
1998
|
| gptkbp:hasCompany |
gptkb:Ironwood_Pharmaceuticals,_Inc.
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ: IRWD
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US46333X1081
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:marketCap |
mid-cap
|
| gptkbp:product |
LINZESS (linaclotide)
|
| gptkbp:stockSymbol |
gptkb:IRWD
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_IRWD
|
| gptkbp:website |
https://www.ironwoodpharma.com/
|
| gptkbp:bfsParent |
gptkb:Ironwood_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|